Literature DB >> 20422763

Tuberculosis-resistance, funding, and drugs.

Talha Burki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422763     DOI: 10.1016/s1473-3099(10)70083-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Structural and chemical basis for enhanced affinity to a series of mycobacterial thymidine monophosphate kinase inhibitors: fragment-based QSAR and QM/MM docking studies.

Authors:  Renata V Bueno; Ney R Toledo; Bruno J Neves; Rodolpho C Braga; Carolina H Andrade
Journal:  J Mol Model       Date:  2012-07-31       Impact factor: 1.810

2.  Drug resistance pattern and associated risk factors of tuberculosis patients in the central province of Iran.

Authors:  Aliasghar Farazi; Masoomeh Sofian; Nader Zarrinfar; Fatemeh Katebi; Seyed Davood Hoseini; Roohollah Keshavarz
Journal:  Caspian J Intern Med       Date:  2013

3.  Epidemiology of anti-tuberculosis drug resistance in a Chinese population: current situation and challenges ahead.

Authors:  Yan Shao; Dandan Yang; Weiguo Xu; Wei Lu; Honghuan Song; Yaoyao Dai; Hongbing Shen; Jianming Wang
Journal:  BMC Public Health       Date:  2011-02-17       Impact factor: 3.295

4.  Predictors of multidrug resistant tuberculosis among adult patients at Saint Peter Hospital Addis Ababa, Ethiopia.

Authors:  Muluken Dessalegn; Ermias Daniel; Sileshi Behailu; Maereg Wagnew; Josephat Nyagero
Journal:  Pan Afr Med J       Date:  2016-11-26

5.  Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria.

Authors:  Olusola Adedeji Adejumo; Bolanle Olusola-Faleye; Victor Adepoju; Abimbola Bowale; Sunday Adesola; Ayodeji Falana; Henry Owuna; Kehinde Otemuyiwa; Shafaatu Oladega; Oluwatosin Adegboye
Journal:  Afr Health Sci       Date:  2018-09       Impact factor: 0.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.